Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]

Core Insights - The fourth-quarter earnings season is ongoing, with major pharmaceutical companies set to announce their results, including AstraZeneca, Incyte, Gilead Sciences, Vertex Pharmaceuticals, and Moderna [1] Industry Overview - Several large pharmaceutical companies such as Johnson & Johnson, Lilly, AbbVie, Biogen, Merck, and Amgen reported better-than-expected fourth-quarter results, surpassing estimates for both earnings and revenues. In contrast, Novartis and Sanofi had mixed results, with earnings exceeding estimates but revenues falling short [2] - As of February 4, 40% of companies in the Medical sector, representing 73.9% of the sector's market capitalization, reported quarterly earnings. Among these, 87.5% exceeded earnings estimates, and 75% surpassed revenue estimates. Year-over-year, earnings increased by 3.3%, while revenues rose by 9.5%. Overall, fourth-quarter earnings for the Medical sector are expected to decline by 1.5%, while sales are projected to increase by 9.1% compared to the previous year [3] Company-Specific Insights AstraZeneca - AstraZeneca's performance has been mixed, with earnings beating estimates in two of the last four quarters, meeting once, and missing once, resulting in an average surprise of 3.81%. The consensus estimate for fourth-quarter sales is $15.78 billion, with earnings expected at $2.18 per share [5] - Key medicines, particularly cancer drugs and diabetes medicine, are expected to drive fourth-quarter sales, supported by strong demand trends [7] - AstraZeneca is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [8] Incyte - Incyte has a mixed history of earnings surprises, beating estimates in three of the last four quarters, with an average surprise of 14.35%. The consensus estimate for fourth-quarter sales is $1.35 billion, with earnings expected at $1.94 per share [9] - Strong sales of Jakafi and expected growth in Opzelura sales are likely to contribute to revenue growth in the fourth quarter [11][12] - Incyte is also set to report its fourth-quarter and full-year 2025 earnings on February 10 [12] Gilead Sciences - Gilead Sciences has a mixed earnings surprise history, beating estimates in three of the last four quarters, with an average surprise of 7.80%. The consensus estimate for fourth-quarter sales is $7.57 billion, with earnings expected at $1.83 per share [13] - Increased sales from Biktarvy and Descovy, along with growth in the Liver Disease portfolio, are anticipated to drive top-line growth [14] - Gilead is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [15] Vertex Pharmaceuticals - Vertex has a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 2.01%. The consensus estimate for fourth-quarter sales is $3.17 billion, with earnings expected at $5.07 per share [16] - Revenue growth is likely to be driven by higher sales of its cystic fibrosis medicine, Trikafta, and contributions from newer drugs [18] - Vertex is set to report its fourth-quarter and full-year 2025 results on February 12 [19] Moderna - Moderna has a strong earnings surprise history, beating estimates in all of the last four quarters, with an average surprise of 31.45%. The consensus estimate for fourth-quarter sales is $661.4 million, with expected earnings showing a loss of $2.60 per share [20] - Revenue is expected to be primarily driven by sales of COVID-19 vaccines, although demand has declined recently [22] - Moderna is scheduled to report its fourth-quarter and full-year 2025 earnings on February 13 [23]

Harris Associates L.P. was founded in 1976 by dedicated investment professionals who believed that delivering successful investment results for clients requires a consistent investment philosophy, a commitment to superior investment research and a high level of customer service. Our roster of clients has grown over the years, but these basic beliefs remain unchanged. We are value investors who believe that, over time, the price of a stock will rise to reflect the value of the underlying company. In construc ...

Economic Data - The People's Bank of China will release January CPI and PPI on February 11 [1] - The National Bureau of Statistics will publish the monthly report on January commodity residential sales price index on February 13 [1] - Financial data including January social financing and new RMB loans will also be released next week [1] - In the US, December retail sales month-on-month will be announced on February 10, followed by January unemployment rate and non-farm employment data on February 11 [1] Earnings Reports - The US earnings season continues with several notable companies reporting next week, including BP, Barclays, Marriott, Coca-Cola, and AstraZeneca on February 10 [2] - Other companies such as NetEase, Youdao, and Total will report on February 11, while TripAdvisor and Hyatt will report on February 12 [2] - In Hong Kong, SMIC will report earnings on February 10, followed by Budweiser APAC and NetEase Cloud Music on February 11 [2] New Stock Issuance - One new stock, Tongbao Optoelectronics, will be available for subscription on February 9, with Ai De Technology listing on the Beijing Stock Exchange on February 10 [2] - Several new stocks will list in Hong Kong, including Lanke Technology on February 9 and Aixin Yuanzhi on February 10 [2] Stock Unlocking - A total of 33 restricted stocks will be unlocked next week, with a total market value exceeding 36 billion yuan, led by Hunan YN with 24.096 billion yuan [3][10] Central Bank Operations - The central bank will have 4.055 billion yuan of reverse repos maturing next week, with specific amounts maturing each day [3][10] Government Bonds - The Ministry of Finance will issue the first phase of RMB government bonds in Hong Kong on February 11, with a scale of 14 billion yuan [13]

Group 1: Market Overview - The Stoxx 600 index in Europe is near record highs, having recorded its 7th positive week in eight, contrasting with the significant declines in U.S. tech stocks [1] - The S&P 500 has dropped nearly 30% from its peak in October 2025, while European stocks appear more resilient [2] Group 2: Corporate Earnings and M&A Activity - UniCredit is a significant player in European M&A, with minority stakes in Commerzbank and Alpha Bank yielding around 20% returns on investment [3] - Commerzbank's CEO indicated that a deal with UniCredit is "not sensible" due to the high valuation of the German bank [4] - L'Oreal is reporting earnings and may pursue acquisitions, having raised 3 billion euros for M&A financing, and recently increased its stake in Galderma [9] Group 3: Healthcare Sector Developments - AstraZeneca is focusing on the Chinese market for weight-loss drugs, while Philips aims to maintain a positive performance with new AI tools [7] - There are concerns following a sell-off in Novo Nordisk shares, which may impact investor sentiment towards AstraZeneca and Philips [7]

来源：新浪财经-鹰眼工作室 受理号JXHL2600033药品名称依普隆特生钠注射液药品类型化药申请类型进口注册分类2.4企业名称 AstraZeneca AB;AstraZeneca Global R&D (China) Co., Ltd.;承办日期2026年2月7日 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 国家药品监督管理局药品审评中心数据显示，2026年2月7日，AstraZeneca AB的依普隆特生钠注射液申 请已获受理，受理号为JXHL2600033。 股东名称持股比例认缴出资额认缴出资日期首次持股日期阿斯利康大陆有限公司 ASTRAZENECA CONTINENT B.V.100%5000万元人民币2021年4月7日 天眼查数据显示，AstraZeneca Global R&D (China) Co., Ltd.成立日期2021年04月07日，法定代表人何 静，所属行业为医学研究和试验发展，企业类型为有限责任公司( ...

Group 1 - Major earnings reports are scheduled for next Tuesday from AstraZeneca PLC, Coca-Cola Company, and S&P Global Inc., with a focus on healthcare and technology sectors [1] - Wednesday will feature earnings from McDonald's Corporation, T-Mobile US Inc., and Shopify Inc. pre-market, followed by Cisco Systems Inc. after market close [1] - The week will conclude on Friday with significant energy reports from Enbridge Inc and TC Energy Corporation [1]

Group 1 - Deutsche Bank raised the target price for AstraZeneca from 11,000 pence to 11,500 pence [1]

在易感个体中，瓜氨酸化蛋白会激活T细胞驱动的一系列事件，促进B细胞成熟与活化，进而产生致病 性抗瓜氨酸化蛋白抗体（ACPA）。ACPA与更差的预后相关，常表现为更严重的关节损伤和快速进展 的病程。在体外实验中，AZD1163能抑制RA患者血清和滑液中存在的蛋白质瓜氨酸化及升高的PAD活 性。 根据ClinicalTrials官网，阿斯利康正在开展AZD1163治疗类风湿关节炎患者的一项2期临床研究。本次该 产品在中国获批临床，意味着其在中国的临床研究即将开展。 2025 ACR年会首次公布了AZD1163在健康志愿者中的安全性、耐受性、药代动力学特性及其对系统性 PAD酶活性影响的药效学数据研究。研究表明，AZD1163的暴露量呈剂量比例性增加，皮下给药后最大 浓度出现在第10天。皮下给药的生物利用度估计为65%。平均系统清除率为0.15升/天，平均消除半衰期 为38天。观察到对PAD2/4活性显著且剂量依赖性的抑制，最大抑制率超过95%，证实了靶标结合。在 AZD1163接受者中，抗药物抗体（ADA）发生率较低，为6.7%。不良事件较少，剂量递增耐受性良 好。 智通财经APP获悉，近日，中国国家药监局药品审 ...

【环球网财经 记者 陈超】英国消费者在牛津街排队购买泡泡玛特盲盒，中国生物科技实验室里阿斯利康的科学家正在研发新一代细胞疗法，中英商 业合作正在打破地缘政治的迷雾，回归互利共赢的商业本质。 千亿美元贸易压舱 1月28日，英国首相斯塔默对中国进行正式访问，这是英国首相时隔8年再次访华。此次访问的背景是中英双边经贸关系的深厚基础。根据中国海关总 署和英国国家统计局的数据，中英双边货物贸易额达到1037亿美元，服务贸易额有望突破300亿美元，双向投资存量近680亿美元。 此次访问团队由50余家英国顶尖企业高管和机构代表组成，覆盖金融、能源、制药、创意产业等关键领域。双方签署了多项贸易投资合作成果文件， 并同意年内重启战略对话、经济财金对话等三项高级别机制。这些动作为长期合作建立了更稳定的制度框架，其核心目的之一，正是回应企业界 对"稳定、可预期环境"的迫切需求，为后续的具体商业合作扫除障碍、注入确定性。 值得一提的是，此次访问达成的制度性共识，在访问期间就已催生出具体的企业合作。在贸易便利化方面，京东集团与英中贸易协会在中英商务论坛 上签署战略合作协议，旨在利用京东的电商生态与物流网络，助力更多英国品牌高效触达中国 ...